Arrival to the Embassy of France

By Course Director Professor Patrick Rossignol (Monaco, MON) on behalf of the scientific committee

Moderators: George Bakris (Chicago, USA) & Glenn Chertow (Stanford, USA)

Speakers (10 minutes each):

• Investigator’s perspective: Hiddo Heerspink Lambers (Groningen, NED)

Discussants (5 minutes each):

• Statistician’s perspective: Tom Greene (Salt Lake City, USA)

• Investigator’s perspective: Matt Weir (Baltimore, USA)

• Investigator’s perspective: Marc Froissart (Lausanne, SUI)

• Statistician’s perspective: Tim Friede (Göttingen, GER)

• Industry perspective: Jerome Rossert (AstraZeneca, USA), Maria Borentain (Bayer, USA) & Svenja Seide (Boehringer Ingelheim, GER)

• Regulators’ perspective: Kiyoshiro Tanaka (PMDA, JPN) & Frank Holtkamp (EMA, NED)

Panel discussion with all of the above

In the lobby of the Maison Française

Moderator: Christoph Wanner (Würzburg, GER) & Meg Jardine (Sydney, AUS)

Which is/are the most suitable triple/quadruple combination therapy for CKD patients (with or without diabetes) acknowledging the two/three recommended pillars (ACEI/ARB, SGLT2i, +/- nsMRA, to be initiated simultaneously vs sequentially ?), and new molecules /targets being developed (GLP1 RA, ASI, nsMRAs, endothelin antagonists): which sponsors (industry vs. academia) and trial design consideration (registration vs pragmatic trials, potentially embedded in registries) to ultimately change guidelines and medical practices ?

Speakers (10 minutes each):

• Investigator viewpoint : Vlado Perkovic (Sydney, AUS)

• Investigator viewpoint: George Bakris (Chicago, USA)

Discussants (5 minutes each):

• Funder’s perspective: Harold Feldman (PCORI, USA)

• Industry perspective: Jerome Rossert (AstraZeneca, USA), Maria Borentain (Bayer, USA), Fred Yang (KBP Biosciences, USA) & Ekaterina Sokareva (Novo Nordisk, DEN)

• Regulator’s perspective: Toshiyuki Takahashi (PMDA, JPN)

Panel discussion with all the above

In the lobby of the Maison Française

Moderator: Vlado Perkovic (Sydney, AUS)

Capitalysing on several positive trials, how to best define a therapeutic strategy and next trials?

Speakers (10 minutes each):

• Investigator’s perspective: Jürgen Floege (Aachen, GER)

• Investigator’s perspective: Jonathan Barratt (Leicester, GBR)

Discussants (5 minutes each):

• Investigator’s perspective: Dana Rizk (Birmingham, USA )

• Industry perspective: Radko Komers (Travere, USA), Kerry Cooper (Vera Therapeutics, USA), Jeffrey Hafkin (Otsuka US)

• Regulators’ perspective: Yaa Oppong (FDA, USA), Toshiyuki Takahashi (PMDA, JPN) & Frank Holtkamp (EMA, NED)

Panel discussion with all the above

In the lobby of the Maison Française

Moderator: Hiddo Heerspink Lambers (Groningen, NED)

Speakers (10 minutes each):

• Investigator’s perspective: Joseph Bonventre (Boston, USA)

Discussants (5 minutes each):

• Investigator’s perspective: Mathias Kretzler (Ann Arbor, USA)

• NIDDK perspective: Ivonne Schulmann (NIDDK, USA)

• Industry perspective: Paul Hockings (Antaros Medical, SWE) & Erwin Berthier (Tasso Inc, USA)

Panel discussion with all the above

Moderator: Meg Jardine (Sydney, AUS)

Speakers (10 minutes each):

• Investigator’s perspective: Glenn Chertow (Stanford, USA)

• IRB’s perspective: Andrew McLachlan (Sydney, Australia)

• Investigator’s perspective: Amanda Siriwardana (Sydney, AUS)

Discussants (5 minutes each):

• Investigator’s perspective: Amit Garg (London, CAN)

• KHI perspective: Uptal Patel (KHI, USA)

• NHLBI perspective: Yves Rosenberg (NHLBI, USA)

• CRO perspective: Cassandra Kennedy (Fortrea, USA)

• Industry perspective: Dustin Little (AstraZeneca, USA)

Panel discussion with all the above

In the lobby of la Maison Française

In the Lobby of la Maison Française

Moderators: Prabir Roy-Chaudhury (Chapel Hill, USA) & Patrick Rossignol (Monaco, MON)

Speakers (8 minutes each):

• Lessons from the latest major outcome randomized trials in hemodialysis (challenges and opportunities)

  • Insights from Convince (Device) Peter Blankestijn (Utrecht, NED)

  • Insights from Alchemist (drug) Patrick Rossignol (Monaco, MON)

  • Creating an Innovation Substrate for ESKD: Phaneth Keo (Fresenius Medical Care, USA)

Discussants (4 minutes each):

• Investigator’s perspective: My ideal patient for Hemodiafiltration and Next Steps Needed: Michel Jadoul (Brussels, BEL)

• Investigator’s perspective: Is there a role for MRA’s in Hemodialysis Patients and Next Steps Needed: Jule Pinter (Würzburg, GER)

• Industry perspective: Endo AVFs and DCBs: Why-Who-When-What : Lindsay Downing (Becton Dickinson, USA)

• Industry perspective: Patient Centered Innovation: What does it Really Mean?: Despina Rüssmann (CSL Vifor, SUI)

• NIDDK perspective: Creating an Innovation Substrate for Dialysis and Vascular Access: Dany Gossett (NIDDK, USA)

• Regulator's perspective: Optimizing the Regulatory Substrate for the Next Generation of Dialysis and Vascular Access Products: Robert Lee (FDA, USA)

• Patient's perspective: A Patients Perspective on Quality in Dialysis and Vascular Access: Vanessa Evans (Boston, USA)

• Value Based Care Perspective: Discovery and Process of Care Innovation as Drivers of Value Based Care: Rajiv Poduval (Panoramic Health, USA)

Panel discussion with all of the above

In the lobby of la Maison Française

Moderator: Vlado Perkovic (Sydney, AUS)

Speakers (10 minutes each):

• Investigator’s perspective: Peter Rossing (Copenhagen, DEN)

Discussants (5 minutes each):

• Hiddo Heerspink Lambers (Groningen, NED)

• Industry perspective: Thomas Idorn (Novo Nordisk, DEN)

Panel discussion with all the above

In the lobby of la Maison Française

Moderators: Mathieu Legrand (San Francisco, USA) & (Patrick Rossignol, Monaco, MON)

Speakers (10 minutes each):

Lessons from the latest major outcome randomized trials in AKI:

• The ADQI meeting on clinical trials endpoints: Guiding principles: Marlies Ostermann (London, GBR)

• Insights from STARRT-AKI trial: Sean Bagshaw (Edmonton, CAN)

Discussants (5 minutes each):

• Investigator’s perspective: Sradha Kotwal (Sydney, AUS)

• Investigator’s perspective: Amit Garg (London, CAN)

• 90-day redmissions with the NIH ongoing trial: Chirag Parikh (Baltimore, USA)

• Patient’s perspective: D’Arcy Duquette (Calgary, CAN)

• Industry perspective: NEUTRALIZE-AKI: Kevin Chung (SeaStar Medical, USA) & Juliane Bernholz (AM-Pharma, NED)

• Regulator’s perspective: Frank Holtkamp (EMA, NED)

• Payer’s perspective: Abigail Ryan (CMS, USA)

Panel discussion with all of the above

In the lobby of the Maison Française

Moderators: Dana Fuhrman (Pittsburgh, USA) & Sean Bagshaw (Edmonton, CAN)

Speakers (10 minutes each):

Identification of Core Outcome Domains for future COS in AKI:

• Methodology for COS generation: Bruno Garcia (Brussels, BEL)

• Domains that matter: Natalje Stanski (Cincinatti, USA)

Discussants (5 minutes each):

• Repair domain/biomarkers for AKI in transplant: Chirag Parikh (Baltimore, USA)

• Investigator’s perspective: Jay Koyner (Chicago, USA)

• Patient’s perspective: D’Arcy Duquette (Calgary, CAN)

• Industry perspective: Vadim Paluy (Novartis, USA) & Christine Solinsky (Alexion, USA),

• Payer’s perspective: Abigail Ryan (CMS, USA)

Panel discussion with all of the above

Final words by Professor Patrick Rossignol and co-directors, and adjourn